Posts by Peptra Labs Research
BPC-157 in a Harvard Pain Review: 7 Peptides, Little Data
BPC-157, TB-500 and GHK-Cu appear in a 2026 Harvard pain medicine review. Its closing line is that most remain unapproved and human evidence is limited.
GLP-1 in Ulcerative Colitis: 66.7% vs 25.3% at 12 Weeks
GLP-1 receptor agonist users with ulcerative colitis reached remission far more often than matched controls. Weight loss was not associated with it.
Retatrutide Led 3 GLP-1 Drugs on Kidney Fibrosis in Mice
Retatrutide, tirzepatide and semaglutide were run through the same two mouse models of kidney scarring. Each engaged a different pathway.
Tirzepatide Plus TOFA: More Than Additive in Obese Mice
Tirzepatide works by cutting food intake. A 2026 Science Advances paper reports an oral molecule that cuts fat without touching intake, and adds to it.
Semaglutide: 6 Years of EU Reports, Two Unsettled Signals
Semaglutide drew more eye and suicidal ideation reports than dulaglutide in EudraVigilance. A 2024 cohort of 240,000 people found the opposite.
Tirzepatide vs Semaglutide: Liver Outcomes Are Level
Tirzepatide dropped more BMI than semaglutide over 17 months, and hard liver outcomes came out identical: 4.05 versus 4.04 events per 1000 person-years.
Semaglutide and Cognition: 13,007 Records, One Null Result
Semaglutide beat three comparators on a cognitive score in 13,007 psychiatric patients, and tied with the fourth. The fourth also acts on GLP-1.
GHK-Cu: 18 of 20 Studies in a New Review Are Preclinical
GHK-Cu: a 2026 systematic review pooled 20 studies on the copper peptide. Only two were randomised trials, and the authors say so plainly.
Tirzepatide and HFpEF: What 3,308 Matched Patients Show
Tirzepatide-treated men and women with HFpEF differed little on cardiovascular outcomes. The authors say the design cannot show effectiveness by sex.
Avexitide: a GLP-1 Blocker Cuts Hypoglycaemia by 55%
Avexitide blocks the GLP-1 receptor instead of activating it. Amylyx reports a 55% cut in hypoglycaemic events in a 78-participant phase 3 trial.